Unicycive(US:UNCY) Prnewswire·2025-09-06 13:45Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [1][3]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is under scrutiny for overstating its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its OLC NDA [3]. - The company’s stock experienced significant declines following negative FDA communications regarding manufacturing compliance issues [4][5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Unicycive, with the firm encouraging affected investors to discuss their legal rights [1][6]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members [6]. Group 3: Stock Performance - On June 10, 2025, Unicycive's stock fell by $3.68 per share (40.89%) to close at $5.32 after the company disclosed FDA compliance deficiencies [4]. - Following a Complete Response Letter from the FDA on June 30, 2025, the stock dropped by $2.03 per share (29.85%) to close at $4.77 [5].